Significance of Osmoticity in Antibiotic Small-Volume Parenterals

Abstract

Spanish

French

The most common cause of intravenous therapy morbidity is postinfusion phlebitis. It affects 25-70 percent of all hospitalized patients and can result in a prolonged stay. One potential contributing factor to postinfusion phlebitis is that most current intravenous antibiotic products and delivery systems do not consider osmolality. One important contribution hospital pharmacists can make to decreasing postinfusion phlebitis is to control final admixture osmoticity, thus ensuring that antibiotic small-volume parenterals are not causative factors. The purpose here is to discuss how changes in osmolality affect the development of postinfusion phlebitis and to provide hospital pharmacists with ideas for action to provide iso-osmotic formulations.

Keywords

admixture osmoticity iso-osmotic iv admixtures osmolality osmolarity postinfusion phlebitis antibiotic small-volume parenterals

Get full access to this article

View all access options for this article.

References

Turco

. Phlebitis associated with intravenous drug administration. Bull Parenter Drug Assoc 1975; 29: 89–97.

Bass

, Freeman

, Makarewicz

, Sproule

, Fairfull-Smith

. Preventing superficial phlebitis during infusion of crystalloid solutions in surgical patients. Can J Surg 1985; 28: 124–5.

Maki

. Non-infective complications of infusion therapy. Infusion 1978; 2: 89–106.

Friedland

. Infusion-related phlebitis: is the inline filter the solution? N Engl J Med 1985; 312: 113–4.

Eremin

, Marshall

. Complications of intravenous therapy: reduction by buffering of intravenous fluid preparation. Med J Aust 1977; 2: 528–31.

Maki

. Preventing infection in IV therapy. Anesth Analg 1977; 56: 141–53.

Thomas

, Evers

, Racz

. Postinfusion phlebitis. Anesth Analg 1970; 49: 150–9.

Siegel

. Tonicity, osmoticity, osmolality, and osmolarity. In: Gennaro

, ed. Remington's pharmaceutical sciences. 17th ed. Easton, PA: Mack Publishing, 1985: 1459

Hastbacka

, Tammisto

, Elfving

. Infusion thrombophlebitis. Acta Anaesthesiol Scand 1965; 10: 9–30.

10.

Fujiwara

, Kawarasaki

, Fonkalsrud

. Reduction of postinfusion venous endothelial injury with intralipid. Surg Gynecol Obstet 1984; 158: 57–65.

11.

Larson

, Lunche

, Tran

. Correlates of i.v. phlebitis. NITA 1984; 7: 203–5.

12.

Gazitua

, Wilson

, Bistrian

. Factors determining peripheral vein tolerance to amino acid infusions. Arch Surg 1979; 114: 897–900.

13.

Rapp

. Osmolality of small-volume intravenous admixtures. Paper presented at the 43rd annual meeting of the American Society of Hospital Pharmacists. June 1-5, 1987, Denver, CO.

14.

Hershey

, Tomford

, Mclaren

. The natural history of intravenous catheter-associated phlebitis. Arch Intern Med 1984; 144: 1373–5.

15.

Findlay

, Dvorak

, Kagey-Sobotka

. Hyperosmolar triggering of histamine release from human basophils. J Clin Invest 1981; 67: 1604–13.

16.

Wermeling

, Rapp

, Deluca

. Osmolality of small-volume intravenous admixtures. Am J Hosp Pharm 1985; 42: 1739–44.

17.

Baptista

, Gallagher

, Sesin

. Infusion system tested for phlebitis potential. IV Ther News 1984; 11: 14–6.

18.

Jarrard

, Goodner

, Piazza

. The syringe infusion pump system: its effect on phlebitis rates. NITA 1987; 10: 29–33.

19.

Rapp

, Powers

, Tolbert

. Postinfusion phlebitis associated with a syringe system versus minibags. Clin Pharm 1986; 5: 408–11.

20.

Davern

, Kubica

. Controlling drug costs: administrative and clinical strategies. Top Hosp Pharm Manage 1984; 3: 49–59.

21.

Douglas

. Adverse drug reactions can prolong patient stay. Mod Healthcare 1984; 14: 100.

22.

Joint Commission on Accreditation of Hospitals. Accreditation manual for hospitals. Chicago: Joint Commission on Accreditation of Hospitals, 1987: 124–5.